comparemela.com
Home
Live Updates
Federal Circuit Affirms Obviousness of Rifaximin Polymorph P
Federal Circuit Affirms Obviousness of Rifaximin Polymorph P
Federal Circuit Affirms Obviousness of Rifaximin Polymorph Patents and Denial of Motion to Modify Judgment After Post-Trial Patented Indication Carve Out | Mintz - Intellectual Property Viewpoints
In a precedential opinion issued on April 11, 2024 in Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals Inc., Nos. 22-2153, 23-1952, the U.S. Court of Appeals for the Federal...
Related Keywords
Delaware ,
United States ,
Richardg Andrews ,
,
Alvogen Inc ,
Salix Pharmaceuticals Ltd ,
Alkemlaboratories Ltd ,
Norwich Pharmaceuticals Inc ,
Us Court ,
Us District Court ,
Salix Pharmaceuticals ,
Pharmaceuticals Inc ,
Federal Circuit ,
Laboratories Ltd ,
Defendant Norwich ,
Abbreviated New Drug Application ,
Orange Book ,
Judge Richard ,
Judge Andrews ,
Federal Rule ,
Civil Procedure ,
Polymorph Patents Affirmed Invalid ,
Motion Denial Affirmed ,